We have a variety of topics for you this week! We tackle red light therapy, polatuzumab olatuzumab vedotin in relapsed or refractory diffuse large b-cell lymphoma; we have a hematology/oncology question of the week from Dr. Emerson Chen of OHSU; and we sit down with Dr. Ali Khaki of the Fred Hutchinson Cancer Research Center to discuss his recent paper critiquing TAILORx.

Pola for DLBCL: doi.org/10.1200/JCO.19.00172
Financial COI on Twitter: doi.org/10.1001/jamainternmed.2016.8467
Ignoring Valuable Data: doi.org/10.6004/jnccn.2019.7363

Back us on Patreon! www.patreon.com/plenarysession

2.35 BONUS! How to Keep Up with the New Information in Medicine

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com